 "pharma")
Dr Reddy's Laboratories Limited announced on Friday that it has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, pursuant to which the company would sell its US and select territory rights for Zembrace Symtouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray). Earlier these products were commercialised through Dr Reddys' wholly owned subsidiary Promius Pharma.
"Under the agreement, Dr Reddy's will receive $70 million as up-front consideration, $ 40.5 million in near-term milestones and additional financial considerations including, existing contractual obligation and inventory. Subsequently Dr Reddy's will receive sales based royalties on a quarterly basis," the company said.
The
